ALBANY, N.Y.--(BUSINESS WIRE)--
AngioDynamics (NASDAQ: ANGO), a leading provider of innovative,
minimally invasive medical devices for vascular access, surgery,
peripheral vascular disease and oncology, announced presentations on
NanoKnife® System clinical experience were given at the
Society of Surgical Oncology (SSO) 2012 conference that took place March
21-24, 2012, in Orlando, Fla.
An oral presentation titled, "Image Guided Irreversible Electroporation
in Locally Advanced Pancreatic Cancer: Improved Overall Survival," was
presented by Dr. Robert Martin, University Of Louisville, Department of
Surgery, Division of Surgical Oncology, Louisville, Ky. Additional
authors included Doctors David Hays and Whitney Goodwin, Baptist Health,
Little Rock, Ark.; and Doctors Kellie McFarlin, Madhu Prasad and Vic
Valanovich, Henry Ford Hospital, Detroit, Mich.
In connection with a registry administered by the University of
Louisville, Department of Surgery, Division of Surgical Oncology, 44
patients underwent procedures with the NanoKnife System for unresectable
pancreatic cancer from December 2009 to October 2010. Overall survival
was evaluated and compared to 85 matched stage three patients treated
with standard therapy defined as chemotherapy and radiation therapy
The authors noted that ninety percent of the patients treated with the
NanoKnife System had chemotherapy alone, or chemo-radiation therapy, for
a median duration of five months before a procedure with the NanoKnife
System. Seventy-three percent underwent chemotherapy or chemo-radiation
after a procedure with the NanoKnife System. The 90-day mortality in
patients who had procedures with the NanoKnife System was two percent.
Comparing patients with NanoKnife System procedures to those receiving
standard therapy, the authors reported a significant improvement in
local progression-free survival, 14 versus six months. Improvement also
was reported for distant progression-free survival, 15 versus nine
months. Overall survival was 20 months versus 13 months.
A poster presentation, titled "The Successful Implementation of
Irreversible Electroporation for Tissue Ablation in Primary and
Secondary Tumors of the Liver and Pancreas," also was given. The authors
are Doctors Gary Deutsch; H. Walden, Mansoor Beg, Charles Conte, James
Sullivan and John Wang, North Shore University Hospital, Hofstra-NSLIJ
School of Medicine, Manhasset, N.Y.
Abstracts for the presentations may be found via the following link and
are listed as abstract 18 and P243 respectively:
In the United States, NanoKnife has been cleared by the FDA for use in
the surgical ablation of soft tissue. NanoKnife has not been cleared for
the treatment or therapy of a specific disease or condition. This
document may discuss the use of NanoKnife for specific clinical
indications for which it is not cleared in the United States at this
AngioDynamics, Inc. is a leading provider of innovative, minimally
invasive medical devices used by professional healthcare providers for
vascular access, surgery, peripheral vascular disease and oncology.
AngioDynamics' diverse product lines include market-leading ablation
systems, vascular access products, angiographic products and
accessories, angioplasty products, drainage products, thrombolytic
products and venous products. More information is available at www.AngioDynamics.com.
This release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements
regarding AngioDynamics' expected future financial position, results of
operations, cash flows, business strategy, budgets, projected costs,
capital expenditures, products, competitive positions, growth
opportunities, plans and objectives of management for future operations,
as well as statements that include the words such as "expects,"
"reaffirms," "intends," "anticipates," "plans," "believes," "seeks,"
"estimates," "optimistic," or variations of such words and similar
expressions, are forward-looking statements. These forward looking
statements are not guarantees of future performance and are subject to
risks and uncertainties. Investors are cautioned that actual events or
results may differ from AngioDynamics' expectations. Factors that may
affect the actual results achieved by AngioDynamics include, without
limitation, the ability of AngioDynamics to develop its existing and new
products, technological advances and patents attained by competitors,
future actions by the FDA or other regulatory agencies, domestic and
foreign health care reforms and government regulations, results of
pending or future clinical trials, overall economic conditions, the
results of on-going litigation, the effects of economic, credit and
capital market conditions, general market conditions, market acceptance,
foreign currency exchange rate fluctuations, the effects on pricing from
group purchasing organizations and competition, the ability of
AngioDynamics to integrate purchased businesses, as well as the risk
factors listed from time to time in AngioDynamics' SEC filings,
including but not limited to its Annual Report on Form 10-K for the year
ended May 31, 2011, and AngioDynamics' Form 10-Q for the quarterly
period ended November 30, 2011. AngioDynamics does not assume any
obligation to publicly update or revise any forward-looking statements
for any reason.
AngioDynamics provided grants in support of the studies referred to in
Joseph Gersuk, CFO, 800-772-6446 x1608
EVC Group, Inc.
EVC Group, Inc.
Source: AngioDynamics, Inc.
News Provided by Acquire Media